drugset / Trial / NCT03583307

Efficacy and Safety of Sirolimus to Vascular Anomalies

NCT03583307

Completed 126 enrolled West China Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of Sirolimus in complicated vascular anomalies in Chinese children

Timeline

Start
2018-06-01
Primary completion
2021-02-19
Completion
2021-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.8 mg/m2 Oral

Indications

No indication recorded.